Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College
Attending Physician, Department of Medicine, Memorial Sloan-Kettering Cancer Center
Related Videos
Video
How do we motivate physicians and patients to deploy biosimilars as their go-to therapies?
How do we motivate physicians and patients to deploy biosimilars as their go-to therapies?
Video
In general, can we extrapolate efficacy of biosimilars across all the disease states for which the originator has indication?
Video
What does the landscape for biosimilars look like for RA and other connective tissue disorders look like?
Video
Can you discuss the immunogencity issues —i.e., anti-drug antibodies (ADAs) — for biosimilars vs reference biologics; and how we can apply results of clinical trials comparing biosimilar anti-TNFs to the front lines of drug selection and RA patient care?
Video
How will we make drug selection and sequencing choices now that biosimilars, including ant-TNF agents, are available?
Video
What factors fueled the introduction of biosimilars?
What factors fueled the introduction of biosimilars?
Video
How should clinicians managing patients with RA select among available agents, including biosimilars for infliximab?
Video
What is the real world data supporting the use of infliximab biosimilars such as INFLIXIMAB-DYYB?
What is the real world data supporting the use of infliximab biosimilars such as INFLIXIMAB-DYYB?
Video
The naming of the biosimilars is creating a lot of confusion. Can you give us a roadmap for making sense of the naming strategies for these drugs?
